74427-22-8

Basic information

• Product Name: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE
• Synonyms: 2,2-DIFLUOROETHYL TRIFLATE;2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE;2,2-DIFLUOROETHYL TRIFLUOROMETHANESULPHONATE;2,2-Difluoroethyl trifluoromethanesulphonate 98%;2,2-Difluoroethyltrifluoromethanesulphonate98%;Trifluoromethanesulfonic acid 2,2-difluoroethyl ester;Methanesulfonic acid, 1,1,1-trifluoro-, 2,2-difluoroethyl ester
• CAS NO: 74427-22-8
• Molecular Formula: C₃H₃F₅O₃S
• Molecular Weight: 214.11
• Mol File: 74427-22-8.mol

Chemical Properties

• Boiling Point: 118-120°C
• Flash Point: 32.1°C
• Appearance: /
• Density: 1.6150
• Vapor Pressure: 12.4mmHg at 25°C
• Refractive Index: 1.3300-1.3340
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE(74427-22-8)
• EPA Substance Registry System: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE(74427-22-8)

Safety Data

• Hazard Codes: T,Xi
• Statements: 20/21/22-36/37/38-23/24/25
• Safety Statements: 23-26-36-63-45-36/37/39
• RIDADR: 2810
• HazardClass: IRRITANT-HARMFUL
• PackingGroup: II
• Hazardous Substances Data: 74427-22-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE is used as a reagent for the preparation of kinesin spindle protein inhibitors. These inhibitors are crucial in the treatment of taxane-refractory cancer, a type of cancer that has become resistant to the effects of taxane, a common chemotherapy drug. 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE's ability to inhibit the kinesin spindle protein disrupts cell division, thereby preventing the growth and spread of cancer cells.
Additionally, 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE is used as a synthetic building block for the creation of MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Pseudomonas aeruginosa is a type of bacteria that can develop resistance to multiple antibiotics, making it difficult to treat. The efflux pump inhibitors synthesized using 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE help to counteract this resistance by blocking the bacteria's ability to expel antibiotics, thus enhancing the effectiveness of the treatment.

InChI:InChI=1/C3H3F5O3S/c4-2(5)1-11-12(9,10)3(6,7)8/h2H,1H2

Upstream product

• 359-13-7 difluoroethanol 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 1004513-80-7 ethyl {4-[4-[(2,2-difluoroethyl)oxy]-9-(ethyloxy)-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-fluorophenyl}acetate 
• 1004513-88-5 ethyl {3-chloro-4-[4-[(2,2-difluoroethyl)oxy]-9-(ethyloxy)-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetate 
• 1007220-40-7 ethyl (4-{4-chloro-7-[(2,2-difluoroethyl)oxy]-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl}phenyl)-acetate 
• 1027708-07-1 methyl 3-{(2,2-difluoroethyl)[(trans-4-methylcyclohexyl)carbonyl]amino}-5-iodo-2-thiophenecarboxylate 
• 1094568-61-2 methyl 3-{(2,2-difluoroethyl)[(trans-4-methylcyclohexyl)carbonyl]amino}-5-(4-pyrazolo[1,5-a]pyrimidin-2-ylphenyl)-2-thiophenecarboxylate 
• 1041770-41-5 (2S)-N-[1-(2,2-difluoroethyl)piperidin-4-yl]-4-(2,5-difluorophenyl)-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide 
• 937603-38-8 C₁₁H₁₂F₂O₃ 
• 1036374-96-5 C₂₁H₂₂F₃N₃O₄ 
• 1252632-89-5 (2S,4R)-4-(2-chlorobenzenesulfonyl)-1-(2,2-difluoroethyl)pyrrolidine-2-carboxylic acid (1-cyanocyclopropyl)amide 
• 1268342-19-3 3-(trifluoromethyl)-1-{2,4-dimethyl-5-[(2,2-difluoroethyl)sulphanyl]phenyl}-1H-1,2,4-triazole 
• 1279118-06-7 2-(5.5-dimethyl-4,5-dihydroisoxazole-3-sulfonyl)-1-phenylethanone O-(2,2-difluoroethyl)oxime 
• 1342803-58-0 trans-8-chloro-5-(2,2-difluoro-ethyl)-1-[4-(3-fluoro-pyridin-2-yl)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene 
• 1352621-18-1 [4-bromo-3-(2,2-difluoroethoxy)phenyl](morpholin-4-yl)methanone 
• 1400640-64-3 (2-(4-chlorophenyl)-4-(2,2-difluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)(4-isopropoxy-3-methylphenyl)methanone 

Relevant articles and documents

Imidazolium-based protic ionic liquids with perfluorinated anions: Influence of chemical structure on thermal properties

The influence of the cation chemical structure, namely its side chain, on the thermal properties of imidazolium-based protic ionic liquids (PILs) with different perfluorinated anions (trifluoromethanesulfonimide (TFSI), trifluoromethanesulfonic (TFS), and trifluoroacetic (TFA) acids) was studied. With that purpose, twenty-one PILs with various alkyl (methyl-, ethyl-, butyl- and vinyl-) and fluorinated (-CH2CF3, -CH2CHF2, and -CH2CH2F) side chains were successfully synthesized. Special attention was paid to an optimization of their synthesis conditions. The structure of synthesized fluorinated and alkyl-substituted PILs was confirmed by means of nuclear magnetic resonance (NMR) analysis (1D: 1H, 19F, 13C and 2D: 1H – 19F HOESY experiments) and Fourier transform infrared (FTIR) spectroscopy, while PILs thermal behavior was determined by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) in dynamic and isothermal modes. The correlation between the PILs chemical structure and their thermal stability was established. It has been found that an increase of the length of alkyl side chain (methyl- 2F 2 3) leads to a PIL with a higher crystallinity (a higher melting point temperature) and a lower thermal stability. Thus, the best performance in terms of the thermal stability was reached for monofluorinated- (-CH2F) and butyl-TFSI PILs in liquid state: 370 °C and 400 °C, respectively, while the lowest thermal stability was obtained for trifluorinated- (-CF3) and vinyl-TFA PILs in solid state: 145 °C and 129 °C, respectively.

CHEMICAL COMPOUNDS

The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

ESTROGEN RECEPTOR MODULATORS

The specification relates to compounds of Formula (I): (I) 5and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.

N-(2-(4-((1R,3R)-3-METHYL-2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL-1-YL)PHENOXY)ETHYL)PROPAN-1-AMINE DERIVATIVES AND RELATED COMPOUNDS AS SELECTIVE DOWN-REGULATORS OF THE ESTROGEN RECEPTOR FOR TREATING CANCER

The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and to the compounds of Formula (I) for use as selective down-regulators of the estrogen receptor in the treatment of cell proliferative disorders, such as cancer.

OXADIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS

Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

CHEMICAL COMPOUNDS

The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Preparation method of 2-(2',2'-difluoroethoxy)-6-(trifluoromethyl)benzene-1-sulfonyl chloride

The invention discloses a preparation method of 2-(2',2'-difluoroethoxy)-6-(trifluoromethyl)benzene-1-sulfonyl chloride. The preparation method comprises following steps: (1) a sulfonyl chloride or a sulfonic anhydride is added into an organic solvent containing 2,2-difluoroethanol and an alkali, and a compound I is obtained via complete reaction, wherein the sulfonyl chloride is selected from alkyl sulfonyl chloride or benzene sulfonyl chloride, and the sulfonic anhydride is selected from alkyl sulfonic anhydride or benzene sulfonic anhydride; (2) m-trifluoromethylphenol, the compound I, and an alkali are added into an organic solvent, an obtained mixture is heated and stirred, and a compound II is obtained via complete reaction; and (3) an accelerant and the compound II are added into an organic solvent, a strong alkali is added, the sulfonyl chloride is added into an obtained reaction solution, and 2-(2',2'-difluoroethoxy)-6-(trifluoromethyl)benzene-1-sulfonyl chloride is obtained via complete reaction and purifying. The preparation method is simple, is high in efficiency, is safe and reliable, and is capable of increasing synthesis efficiency of penoxsulam greatly; and operation is simple and convenient.

Solvent-free synthesis of alkyl and fluoroalkyl sulfonium salts from sulfides and fluoroalkyl trifluoromethanesulfonates

A series of diaryl(fluoroalkyl)sulfonium salts were synthesized from electron-rich diaryl sulfides and fluoroalkyl trifluoromethanesulfonates under solvent-free conditions. Unlike diaryl sulfides, dialkyl and alkyl(aryl) sulfides reacted with fluoroalkyl